VENUS REMEDIES LTD. - 526953 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Venus Remedies Ltd secured Good Manufacturing Practices (GMP ) approval from UNICEF11-03-2024
11-03-2024
Venus Remediesgets marketing authorisation for oncology drugs in Ukraine
Venus Remedies shares close higher on NSE08-03-2024
VENUS REMEDIES LTD. - 526953 - Venus Remedies Receives Marketing Authorizations For Oncology Drug In Ukraine (Asia CIS).
Venus Remedies receives Marketing Authorizations for Oncology Drug in Ukraine (Asia CIS).08-03-2024
Venus Remedies receives disbursement of 7.5 crore under PLI Scheme
Venus Remedies stock inched up by 0.16 per cent on the NSE to trade at 338.25 as of 10.53 am on Wednesday06-03-2024
VENUS REMEDIES LTD. - 526953 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Venus Remedies awarded its first incentive of Rs.7.50 crores under PLI scheme.06-03-2024
VENUS REMEDIES LTD. - 526953 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of financial results for the period ended on 31st December 2023.16-02-2024
VENUS REMEDIES LTD. - 526953 - Financial Results For The Period Ended On 31St December 2023.
Financial Results for the period ended on 31st December 2023.14-02-2024
VENUS REMEDIES LTD. - 526953 - Board Meeting Outcome for Outcome Of Board Meeting Dated 14Th February 2024.
This has reference to the meeting of Board of Directors held on 14th February 2024 inter alia considered and approved the Unaudited Financial Results for the period ended on 31st December 2023 along with Limited Review report. Unaudited Financial Results for the period ended on 31st December 2023 along with Limited Review report are enclosed herewith. Meeting commenced at 04:30 pm and concluded at 07.40pm14-02-2024
VENUS REMEDIES LTD. - 526953 - Venus Remedies Secures Multiple Marketing Authorizations For Key Pharmaceuticals In Ukraine (Asia Cis).
Venus Remedies secures multiple Marketing Authorizations for Key Pharmaceuticals in Ukraine (Asia CIS).12-02-2024